Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Pharmacological MRI to investigate the functional selectivity of 5-HT1A receptor biased agonists.

Vidal B, Bolbos R, Redouté J, Langlois JB, Costes N, Newman-Tancredi A, Zimmer L.

Neuropharmacology. 2019 Nov 26:107867. doi: 10.1016/j.neuropharm.2019.107867. [Epub ahead of print] Review.

PMID:
31783063
2.

From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery.

Sniecikowska J, Newman-Tancredi A, Kolaczkowski M.

Curr Top Med Chem. 2019 Sep 11. doi: 10.2174/1568026619666190911122040. [Epub ahead of print]

PMID:
31544717
3.

18F-F13640 PET imaging of functional receptors in humans.

Colom M, Costes N, Redouté J, Dailler F, Gobert F, Le Bars D, Billard T, Newman-Tancredi A, Zimmer L.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):220-221. doi: 10.1007/s00259-019-04473-7. Epub 2019 Aug 14. No abstract available.

PMID:
31414208
4.

Bell-shaped agonist activation of 5-HT1A receptor-coupled Gαi3 G-proteins: Receptor density-dependent switch in receptor signaling.

Newman-Tancredi A, Cussac D, Ormière AM, Lestienne F, Varney MA, Martel JC.

Cell Signal. 2019 Nov;63:109383. doi: 10.1016/j.cellsig.2019.109383. Epub 2019 Jul 31.

PMID:
31376526
5.

Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model.

Depoortère R, Papp M, Gruca P, Lason-Tyburkiewicz M, Niemczyk M, Varney MA, Newman-Tancredi A.

J Psychopharmacol. 2019 Nov;33(11):1456-1466. doi: 10.1177/0269881119860666. Epub 2019 Jul 10.

PMID:
31290370
6.

Enhanced aggressive phenotype of Tph2 knockout rats is associated with diminished 5-HT1A receptor sensitivity.

Peeters DGA, de Boer SF, Terneusen A, Newman-Tancredi A, Varney MA, Verkes RJ, Homberg JR.

Neuropharmacology. 2019 Jul 15;153:134-141. doi: 10.1016/j.neuropharm.2019.05.004. Epub 2019 May 9.

PMID:
31078489
7.

Serotonin 5-HT1A Receptor Biased Agonists Display Differential Anxiolytic Activity in a Rat Social Interaction Model.

Depoortère R, Bardin L, Varney MA, Newman-Tancredi A.

ACS Chem Neurosci. 2019 Jul 17;10(7):3101-3107. doi: 10.1021/acschemneuro.8b00661. Epub 2019 Apr 2.

PMID:
30929419
8.

Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity.

Sniecikowska J, Gluch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzebska-Wiesek M, Partyka A, Wilczyńska D, Pytka K, Pociecha K, Cios A, Wyska E, Wesołowska A, Pawłowski M, Varney MA, Newman-Tancredi A, Kolaczkowski M.

J Med Chem. 2019 Mar 14;62(5):2750-2771. doi: 10.1021/acs.jmedchem.9b00062. Epub 2019 Mar 2.

PMID:
30721053
9.

Serotonin 5-HT1A Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [18F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats.

Levigoureux E, Vidal B, Fieux S, Bouillot C, Emery S, Newman-Tancredi A, Zimmer L.

ACS Chem Neurosci. 2019 Jul 17;10(7):3108-3119. doi: 10.1021/acschemneuro.8b00584. Epub 2019 Jan 7.

PMID:
30576601
10.

Activation of somatodendritic 5-HT1A autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test.

Zhao Y, Bijlsma EY, Ter Heegde F, Verdouw MP, Garssen J, Newman-Tancredi A, Groenink L.

Psychopharmacology (Berl). 2019 Apr;236(4):1171-1185. doi: 10.1007/s00213-018-5124-0. Epub 2018 Dec 12.

11.

In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.

Vidal B, Fieux S, Redouté J, Villien M, Bonnefoi F, Le Bars D, Newman-Tancredi A, Costes N, Zimmer L.

Neuropsychopharmacology. 2018 Oct;43(11):2310-2319. doi: 10.1038/s41386-018-0145-2. Epub 2018 Jul 6.

12.

18F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging.

Vidal B, Fieux S, Colom M, Billard T, Bouillot C, Barret O, Constantinescu C, Tamagnan G, Newman-Tancredi A, Zimmer L.

Brain Struct Funct. 2018 Jul;223(6):2973-2988. doi: 10.1007/s00429-018-1672-7. Epub 2018 May 5.

PMID:
29730825
13.

Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats.

Newman-Tancredi A, Varney MA, McCreary AC.

Neurochem Res. 2018 May;43(5):1035-1046. doi: 10.1007/s11064-018-2514-y. Epub 2018 Mar 23.

PMID:
29572645
14.

NLX-112, a highly selective 5-HT1A receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT1A receptors, respectively.

Newman-Tancredi A, Bardin L, Auclair A, Colpaert F, Depoortère R, Varney MA.

Brain Res. 2018 Jun 1;1688:1-7. doi: 10.1016/j.brainres.2018.03.016. Epub 2018 Mar 16.

PMID:
29555239
15.

Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT1A receptor biased agonists.

Brys I, Halje P, Scheffer-Teixeira R, Varney M, Newman-Tancredi A, Petersson P.

Exp Neurol. 2018 Apr;302:155-168. doi: 10.1016/j.expneurol.2018.01.010. Epub 2018 Jan 13.

PMID:
29339052
16.

Activity of Serotonin 5-HT1A Receptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like properties.

Jastrzębska-Więsek M, Partyka A, Rychtyk J, Śniecikowska J, Kołaczkowski M, Wesołowska A, Varney MA, Newman-Tancredi A.

ACS Chem Neurosci. 2018 May 16;9(5):1040-1050. doi: 10.1021/acschemneuro.7b00443. Epub 2018 Jan 11.

PMID:
29266914
17.

NLX-112, a highly selective 5-HT1A receptor agonist: Effects on body temperature and plasma corticosterone levels in rats.

Newman-Tancredi A, Depoortère R, Carilla-Durand E, Tarayre JP, Kleven M, Koek W, Bardin L, Varney MA.

Pharmacol Biochem Behav. 2018 Feb;165:56-62. doi: 10.1016/j.pbb.2017.11.002. Epub 2017 Nov 7.

PMID:
29126856
18.

Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain.

Sałat K, Kołaczkowski M, Furgała A, Rojek A, Śniecikowska J, Varney MA, Newman-Tancredi A.

Neuropharmacology. 2017 Oct;125:181-188. doi: 10.1016/j.neuropharm.2017.07.022. Epub 2017 Jul 24.

PMID:
28751195
19.

Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist.

Newman-Tancredi A, Martel JC, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D.

J Pharm Pharmacol. 2017 Sep;69(9):1178-1190. doi: 10.1111/jphp.12762. Epub 2017 Jun 14.

PMID:
28612503
20.

Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.

Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C.

Exp Neurol. 2017 Jun;292:168-178. doi: 10.1016/j.expneurol.2017.03.013. Epub 2017 Mar 23.

PMID:
28342749
21.

Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States.

Yokoyama C, Mawatari A, Kawasaki A, Takeda C, Onoe K, Doi H, Newman-Tancredi A, Zimmer L, Onoe H.

Int J Neuropsychopharmacol. 2016 Dec 30;19(12). pii: pyw079. doi: 10.1093/ijnp/pyw079. Print 2016 Dec.

22.

Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study.

Becker G, Bolbos R, Costes N, Redouté J, Newman-Tancredi A, Zimmer L.

Sci Rep. 2016 May 23;6:26633. doi: 10.1038/srep26633.

23.

Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals.

Vidal B, Sebti J, Verdurand M, Fieux S, Billard T, Streichenberger N, Troakes C, Newman-Tancredi A, Zimmer L.

Neuropharmacology. 2016 Oct;109:88-95. doi: 10.1016/j.neuropharm.2016.05.009. Epub 2016 May 13.

PMID:
27183968
24.

The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A.

Neuropharmacology. 2016 Jun;105:651-660. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9.

PMID:
26777281
25.

Anti-aggressive effects of the selective high-efficacy 'biased' 5-HT₁A receptor agonists F15599 and F13714 in male WTG rats.

de Boer SF, Newman-Tancredi A.

Psychopharmacology (Berl). 2016 Mar;233(6):937-47. doi: 10.1007/s00213-015-4173-x. Epub 2015 Dec 23.

26.

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM.

Neuropharmacology. 2015 Oct;97:306-11. doi: 10.1016/j.neuropharm.2015.05.033. Epub 2015 Jun 10.

PMID:
26071982
27.

Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs.

McCreary AC, Newman-Tancredi A.

Curr Pharm Des. 2015;21(26):3725-31. Review.

PMID:
26044980
28.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
29.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393
30.

Divergent effects of the 'biased' 5-HT1 A receptor agonists F15599 and F13714 in a novel object pattern separation task.

van Goethem NP, Schreiber R, Newman-Tancredi A, Varney M, Prickaerts J.

Br J Pharmacol. 2015 May;172(10):2532-43. doi: 10.1111/bph.13071. Epub 2015 Feb 27.

31.

A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease.

Becker G, Streichenberger N, Billard T, Newman-Tancredi A, Zimmer L.

CNS Neurosci Ther. 2014 Oct;20(10):930-4. doi: 10.1111/cns.12306. Epub 2014 Jul 9.

32.

Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists.

Abdala AP, Bissonnette JM, Newman-Tancredi A.

Front Physiol. 2014 May 30;5:205. doi: 10.3389/fphys.2014.00205. eCollection 2014.

33.

Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia.

Kołaczkowski M, Mierzejewski P, Bienkowski P, Wesołowska A, Newman-Tancredi A.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun;387(6):545-57. doi: 10.1007/s00210-014-0966-4. Epub 2014 Mar 6.

34.

Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.

Schreiber R, Newman-Tancredi A.

Neurobiol Learn Mem. 2014 Apr;110:72-80. doi: 10.1016/j.nlm.2013.12.015. Epub 2014 Jan 11. Review.

PMID:
24423786
35.

5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.

Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED.

Psychopharmacology (Berl). 2014 Feb;231(4):623-36. doi: 10.1007/s00213-013-3389-x. Epub 2013 Dec 12. Review. Erratum in: Psychopharmacology (Berl). 2014 Feb;231(4):637.

36.

ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Kołaczkowski M, Mierzejewski P, Bieńkowski P, Wesołowska A, Newman-Tancredi A.

Br J Pharmacol. 2014 Feb;171(4):973-84. doi: 10.1111/bph.12509.

37.

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O'Connor JA, Depoortère R.

Neuropharmacology. 2013 Jul;70:338-47. doi: 10.1016/j.neuropharm.2013.02.024. Epub 2013 Mar 13.

38.

Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.

Lemoine L, Becker G, Vacher B, Billard T, Lancelot S, Newman-Tancredi A, Zimmer L.

J Nucl Med. 2012 Jun;53(6):969-76. doi: 10.2967/jnumed.111.101212. Epub 2012 May 10.

39.

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G.

J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16.

PMID:
22178752
40.

In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.

Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.

Psychopharmacology (Berl). 2012 May;221(2):261-72. doi: 10.1007/s00213-011-2569-9. Epub 2011 Dec 3.

PMID:
22147258
41.

Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents.

Depoortère R, Meleine M, Bardin L, Aliaga M, Muller E, Ardid D, Newman-Tancredi A.

Eur J Pharmacol. 2011 Dec 15;672(1-3):83-7. doi: 10.1016/j.ejphar.2011.09.182. Epub 2011 Oct 6.

PMID:
21996314
42.

Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall-Selitto model.

Mico JA, Berrocoso E, Vitton O, Ladure P, Newman-Tancredi A, Bardin L, Depoortère R.

Behav Pharmacol. 2011 Sep;22(5-6):599-606. doi: 10.1097/FBP.0b013e328345ca4e.

PMID:
21841543
43.

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

Huot P, Fox SH, Newman-Tancredi A, Brotchie JM.

J Pharmacol Exp Ther. 2011 Oct;339(1):2-8. doi: 10.1124/jpet.111.184093. Epub 2011 Jul 22. Review.

PMID:
21784889
44.

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Newman-Tancredi A, Kleven MS.

Psychopharmacology (Berl). 2011 Aug;216(4):451-73. doi: 10.1007/s00213-011-2247-y. Epub 2011 Mar 11. Review.

PMID:
21394633
45.

Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain.

Berrocoso E, Mico JA, Vitton O, Ladure P, Newman-Tancredi A, Depoortère R, Bardin L.

Eur J Pharmacol. 2011 Mar 25;655(1-3):46-51. doi: 10.1016/j.ejphar.2011.01.022. Epub 2011 Jan 28.

PMID:
21277295
46.

Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference.

Rauly-Lestienne I, Lestienne F, Ailhaud MC, Binesse J, Newman-Tancredi A, Cussac D.

Cell Signal. 2011 Jan;23(1):58-64. doi: 10.1016/j.cellsig.2010.08.002. Epub 2010 Aug 17.

PMID:
20727408
47.

Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors.

Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.

Br J Pharmacol. 2010 Aug;160(8):1929-40. doi: 10.1111/j.1476-5381.2010.00738.x.

48.

The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.

Newman-Tancredi A.

Curr Opin Investig Drugs. 2010 Jul;11(7):802-12. Review.

PMID:
20571976
49.

The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity.

Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U.

J Neurochem. 2010 Sep 1;114(5):1323-32. doi: 10.1111/j.1471-4159.2010.06848.x. Epub 2010 Jun 7.

50.

F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.

Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A.

Eur Neuropsychopharmacol. 2010 Sep;20(9):641-54. doi: 10.1016/j.euroneuro.2010.04.005. Epub 2010 May 21.

PMID:
20488670

Supplemental Content

Loading ...
Support Center